company background image
SRPT

Sarepta TherapeuticsNasdaqGS:SRPT Stock Report

Market Cap

US$7.0b

7D

1.9%

1Y

-43.3%

Updated

30 Nov, 2021

Data

Company Financials +
SRPT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

SRPT Stock Overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.

Sarepta Therapeutics Competitors

Moderna

NasdaqGS:MRNA

US$149.4b

Alnylam Pharmaceuticals

NasdaqGS:ALNY

US$21.6b

BioMarin Pharmaceutical

NasdaqGS:BMRN

US$16.0b

Ionis Pharmaceuticals

NasdaqGS:IONS

US$3.9b

Price History & Performance

Summary of all time highs, changes and price drops for Sarepta Therapeutics
Historical stock prices
Current Share PriceUS$79.86
52 Week HighUS$181.83
52 Week LowUS$65.30
Beta1.21
1 Month Change0.92%
3 Month Change2.23%
1 Year Change-43.31%
3 Year Change-39.02%
5 Year Change134.19%
Change since IPO104.77%

Recent News & Updates

Nov 01

Sarepta: Revenue Keeps Rising While We Wait For Functional Data

SRPT has continued growing its revenue line despite not producing placebo compared data. The stock dropped hugely in January after a trial failure and hasn't recovered since. Some have asked if they even need to produce placebo-controlled trial data.

Nov 01
Health Check: How Prudently Does Sarepta Therapeutics (NASDAQ:SRPT) Use Debt?

Health Check: How Prudently Does Sarepta Therapeutics (NASDAQ:SRPT) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

SRPTUS BiotechsUS Market
7D1.9%2.0%-0.9%
1Y-43.3%4.9%23.3%

Return vs Industry: SRPT underperformed the US Biotechs industry which returned 5.3% over the past year.

Return vs Market: SRPT underperformed the US Market which returned 21.3% over the past year.

Price Volatility

Is SRPT's price volatile compared to industry and market?
SRPT volatility
SRPT Average Weekly Movement6.5%
Biotechs Industry Average Movement8.6%
Market Average Movement6.0%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.3%

Stable Share Price: SRPT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: SRPT's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1980866Doug Ingramhttps://www.sarepta.com

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.

Sarepta Therapeutics Fundamentals Summary

How do Sarepta Therapeutics's earnings and revenue compare to its market cap?
SRPT fundamental statistics
Market CapUS$6.95b
Earnings (TTM)-US$486.12m
Revenue (TTM)US$645.56m

10.8x

P/S Ratio

-14.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SRPT income statement (TTM)
RevenueUS$645.56m
Cost of RevenueUS$868.73m
Gross Profit-US$223.17m
ExpensesUS$262.95m
Earnings-US$486.12m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-5.58
Gross Margin-34.57%
Net Profit Margin-75.30%
Debt/Equity Ratio233.2%

How did SRPT perform over the long term?

See historical performance and comparison

Valuation

Is Sarepta Therapeutics undervalued compared to its fair value and its price relative to the market?

14.81x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: SRPT ($79.86) is trading above our estimate of fair value ($79.36)

Significantly Below Fair Value: SRPT is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: SRPT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: SRPT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SRPT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SRPT is overvalued based on its PB Ratio (14.8x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Sarepta Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?

59.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SRPT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: SRPT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SRPT's is expected to become profitable in the next 3 years.

Revenue vs Market: SRPT's revenue (27.7% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: SRPT's revenue (27.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SRPT is forecast to be unprofitable in 3 years.


Past Performance

How has Sarepta Therapeutics performed over the past 5 years?

-30.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SRPT is currently unprofitable.

Growing Profit Margin: SRPT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SRPT is unprofitable, and losses have increased over the past 5 years at a rate of 30% per year.

Accelerating Growth: Unable to compare SRPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SRPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: SRPT has a negative Return on Equity (-103.53%), as it is currently unprofitable.


Financial Health

How is Sarepta Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: SRPT's short term assets ($2.2B) exceed its short term liabilities ($373.4M).

Long Term Liabilities: SRPT's short term assets ($2.2B) exceed its long term liabilities ($1.8B).


Debt to Equity History and Analysis

Debt Level: SRPT has more cash than its total debt.

Reducing Debt: SRPT's debt to equity ratio has increased from 4.6% to 233.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SRPT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if SRPT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Sarepta Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SRPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SRPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SRPT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SRPT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SRPT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Doug Ingram (58 yo)

4.42yrs

Tenure

US$1,291,947

Compensation

Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 26, 2017. Mr. Ingram serves as Director of Relay Therapeutics,...


CEO Compensation Analysis

Compensation vs Market: Doug's total compensation ($USD1.29M) is below average for companies of similar size in the US market ($USD6.23M).

Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: SRPT's management team is considered experienced (2 years average tenure).


Board Members

Experienced Board: SRPT's board of directors are considered experienced (4.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SRPT insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.3%.


Top Shareholders

Company Information

Sarepta Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Sarepta Therapeutics, Inc.
  • Ticker: SRPT
  • Exchange: NasdaqGS
  • Founded: 1980
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$6.954b
  • Shares outstanding: 87.08m
  • Website: https://www.sarepta.com

Number of Employees


Location

  • Sarepta Therapeutics, Inc.
  • 215 First Street
  • Suite 415
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/30 00:14
End of Day Share Price2021/11/29 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.